Dogwood Therapeutics (DWTX) Net Cash Flow (2020 - 2026)

Dogwood Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$3.6 million in Q2 2026.

• On a quarterly basis, Net Cash Flow rose 12.91% year-over-year to -$3.6 million in Q2 2026; TTM through Jun 2026 was -$3.8 million, a 156.03% decrease from a year earlier, with the FY2025 full-year figure at -$8.3 million, down 171.38% from the prior year.
• Net Cash Flow was -$3.6 million for Q2 2026 at Dogwood Therapeutics, down from $6.7 million in the prior quarter.
• The five-year high for Net Cash Flow was $9.2 million in Q4 2024, with the low at -$4.1 million in Q2 2025.
• Average Net Cash Flow over 5 years is -$844655.0, with a median of -$1.6 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow jumped 725.58% in 2024, then sank 410.78% in 2025.
• Over 5 years, Net Cash Flow stood at -$2.8 million in 2022, then jumped by 46.72% to -$1.5 million in 2023, then surged by 725.58% to $9.2 million in 2024, then slumped by 139.22% to -$3.6 million in 2025, then slipped by 0.18% to -$3.6 million in 2026.
• The last three Net Cash Flow figures came in at -$3.6 million (Q2 2026), $6.7 million (Q1 2026), and -$3.6 million (Q4 2025), per Business Quant data.